KR101844623B1 - 안정성이 향상된 오타믹사반 제제 - Google Patents

안정성이 향상된 오타믹사반 제제 Download PDF

Info

Publication number
KR101844623B1
KR101844623B1 KR1020137028419A KR20137028419A KR101844623B1 KR 101844623 B1 KR101844623 B1 KR 101844623B1 KR 1020137028419 A KR1020137028419 A KR 1020137028419A KR 20137028419 A KR20137028419 A KR 20137028419A KR 101844623 B1 KR101844623 B1 KR 101844623B1
Authority
KR
South Korea
Prior art keywords
acid
pharmaceutical composition
methyl
amino
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137028419A
Other languages
English (en)
Korean (ko)
Other versions
KR20140019818A (ko
Inventor
발터 캄
틸 부세머
도리스 안데르트
베른트 퀸
에른슈트-요제프 토트
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20140019818A publication Critical patent/KR20140019818A/ko
Application granted granted Critical
Publication of KR101844623B1 publication Critical patent/KR101844623B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
KR1020137028419A 2011-03-29 2012-03-27 안정성이 향상된 오타믹사반 제제 Expired - Fee Related KR101844623B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305347.4 2011-03-29
EP11305347 2011-03-29
US201161499941P 2011-06-22 2011-06-22
US61/499,941 2011-06-22
PCT/EP2012/055361 WO2012130819A1 (en) 2011-03-29 2012-03-27 Otamixaban formulations with improved stability

Publications (2)

Publication Number Publication Date
KR20140019818A KR20140019818A (ko) 2014-02-17
KR101844623B1 true KR101844623B1 (ko) 2018-04-02

Family

ID=44584895

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137028419A Expired - Fee Related KR101844623B1 (ko) 2011-03-29 2012-03-27 안정성이 향상된 오타믹사반 제제

Country Status (19)

Country Link
US (3) US20120252852A1 (enExample)
EP (1) EP2691075A1 (enExample)
JP (1) JP5993933B2 (enExample)
KR (1) KR101844623B1 (enExample)
CN (1) CN103561723B (enExample)
AR (1) AR085580A1 (enExample)
AU (1) AU2012234323A1 (enExample)
BR (1) BR112013024801A2 (enExample)
CA (1) CA2830962C (enExample)
CO (1) CO6801755A2 (enExample)
EA (1) EA025572B1 (enExample)
IL (1) IL228573A (enExample)
MA (1) MA35050B1 (enExample)
MX (1) MX342324B (enExample)
PH (1) PH12013501991A1 (enExample)
SG (1) SG193932A1 (enExample)
UY (1) UY33975A (enExample)
WO (1) WO2012130819A1 (enExample)
ZA (1) ZA201308061B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252852A1 (en) 2011-03-29 2012-10-04 Sanofi Otamixaban formulations with improved stability
ES2857687T3 (es) * 2013-01-31 2021-09-29 Vertex Pharma Piridona amidas como moduladores de los canales de sodio
DE102013212933B3 (de) * 2013-07-03 2014-11-27 Schaeffler Technologies Gmbh & Co. Kg Lageranordnung in einem Elektromotor
DK3668516T3 (da) 2017-08-16 2021-12-13 Merck Patent Gmbh Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028836A1 (en) * 2000-10-05 2002-04-11 Aventis Pharmaceuticals, Inc. Novel crystalline forms of a factor xa inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030272A (en) * 1960-05-26 1962-04-17 Abbott Lab Stable heaparin solution
PT835657E (pt) 1992-11-27 2004-11-30 Mayne Pharma Usa Inc Composicao injectavel estavel de paclitaxel
CZ297544B6 (cs) 1996-01-02 2007-02-07 Aventis Pharmaceuticals Inc. Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
PE20121401A1 (es) * 2009-07-29 2012-10-25 Sanofi Sa Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
MY161396A (en) 2011-03-29 2017-04-14 Sanofi Sa Benzoic acid salt of otamixaban
US20120252852A1 (en) 2011-03-29 2012-10-04 Sanofi Otamixaban formulations with improved stability

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028836A1 (en) * 2000-10-05 2002-04-11 Aventis Pharmaceuticals, Inc. Novel crystalline forms of a factor xa inhibitor

Also Published As

Publication number Publication date
IL228573A (en) 2017-12-31
BR112013024801A2 (pt) 2016-12-20
EA025572B1 (ru) 2017-01-30
UY33975A (es) 2012-10-31
PH12013501991A1 (en) 2013-11-25
US9993464B2 (en) 2018-06-12
NZ616180A (en) 2015-10-30
KR20140019818A (ko) 2014-02-17
CO6801755A2 (es) 2013-11-29
WO2012130819A1 (en) 2012-10-04
CA2830962A1 (en) 2012-10-04
MX2013011260A (es) 2014-03-27
JP5993933B2 (ja) 2016-09-14
IL228573A0 (en) 2013-12-31
JP2014509621A (ja) 2014-04-21
EA201391406A1 (ru) 2014-02-28
EP2691075A1 (en) 2014-02-05
US20140018398A1 (en) 2014-01-16
ZA201308061B (en) 2015-01-28
MX342324B (es) 2016-09-23
CA2830962C (en) 2019-06-18
AR085580A1 (es) 2013-10-09
US20170224668A1 (en) 2017-08-10
CN103561723A (zh) 2014-02-05
AU2012234323A1 (en) 2013-10-17
MA35050B1 (fr) 2014-04-03
SG193932A1 (en) 2013-11-29
US20120252852A1 (en) 2012-10-04
CN103561723B (zh) 2016-04-20

Similar Documents

Publication Publication Date Title
KR101844623B1 (ko) 안정성이 향상된 오타믹사반 제제
US8962572B2 (en) Bortezomib formulations
FR2853547A1 (fr) Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production
US20230270731A1 (en) Therapeutic compounds and compositions
CA3144541A1 (en) Pharmaceutical development
CA2888625A1 (en) Caspofungin acetate formulations
CN100376251C (zh) 含有甲基维生素b12的冻干制剂及其制备方法
JP6830136B2 (ja) Ｎ−ホルミルピぺリジン含有量が低減されている、及び／又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
JP3917820B2 (ja) オザグレルナトリウム含有注射液およびその安定化方法
TWI551289B (zh) 具有改良之安定性之奧米沙班調配物
NZ616180B2 (en) Otamixaban formulations with improved stability
RU2545903C1 (ru) Фармацевтическая композиция в виде лиофилизата для приготовления раствора для парентерального применения и способ ее получения
RU2666148C1 (ru) Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
CN116782911A (zh) 治疗性化合物、组合物及其使用方法
HK1122214A (en) Formulation for aviptadil
JPWO1989011852A1 (ja) 膵炎等治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210328

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210328

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000